These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 21258360)

  • 1. Application of a novel inhibitor of human CD59 for the enhancement of complement-dependent cytolysis on cancer cells.
    You T; Hu W; Ge X; Shen J; Qin X
    Cell Mol Immunol; 2011 Mar; 8(2):157-63. PubMed ID: 21258360
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Human CD59 inhibitor sensitizes rituximab-resistant lymphoma cells to complement-mediated cytolysis.
    Hu W; Ge X; You T; Xu T; Zhang J; Wu G; Peng Z; Chorev M; Aktas BH; Halperin JA; Brown JR; Qin X
    Cancer Res; 2011 Mar; 71(6):2298-307. PubMed ID: 21252115
    [TBL] [Abstract][Full Text] [Related]  

  • 3. rILYd4, a human CD59 inhibitor, enhances complement-dependent cytotoxicity of ofatumumab against rituximab-resistant B-cell lymphoma cells and chronic lymphocytic leukemia.
    Ge X; Wu L; Hu W; Fernandes S; Wang C; Li X; Brown JR; Qin X
    Clin Cancer Res; 2011 Nov; 17(21):6702-11. PubMed ID: 21918174
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Removal of the tag from His-tagged ILYd4, a human CD59 inhibitor, significantly improves its physical properties and its activity.
    Wu L; Su S; Liu F; Xu T; Wang X; Huang Y; Sun X; Ge X; Chen T; Liu H; Wang C; Chorev M; Xu T; Qin X
    Curr Pharm Des; 2012; 18(27):4187-96. PubMed ID: 22642361
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression of complement inhibitors CD46, CD55, and CD59 on tumor cells does not predict clinical outcome after rituximab treatment in follicular non-Hodgkin lymphoma.
    Weng WK; Levy R
    Blood; 2001 Sep; 98(5):1352-7. PubMed ID: 11520782
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement-mediated cell lysis.
    Golay J; Zaffaroni L; Vaccari T; Lazzari M; Borleri GM; Bernasconi S; Tedesco F; Rambaldi A; Introna M
    Blood; 2000 Jun; 95(12):3900-8. PubMed ID: 10845926
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A complement-dependent cytotoxicity-enhancing anti-CD20 antibody mediating potent antitumor activity in the humanized NOD/Shi-scid, IL-2Rγ(null) mouse lymphoma model.
    Sato F; Ito A; Ishida T; Mori F; Takino H; Inagaki A; Ri M; Kusumoto S; Komatsu H; Iida S; Okada N; Inagaki H; Ueda R
    Cancer Immunol Immunother; 2010 Dec; 59(12):1791-800. PubMed ID: 20714721
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Exploring complement-dependent cytotoxicity by rituximab isotypes in 2D and 3D-cultured B-cell lymphoma.
    Lara S; Heilig J; Virtanen A; Kleinau S
    BMC Cancer; 2022 Jun; 22(1):678. PubMed ID: 35725455
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rituximab (anti-CD20) therapy of B-cell lymphomas: direct complement killing is superior to cellular effector mechanisms.
    Harjunpää A; Junnikkala S; Meri S
    Scand J Immunol; 2000 Jun; 51(6):634-41. PubMed ID: 10849376
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mapping of binding epitopes of a human decay-accelerating factor monoclonal antibody capable of enhancing rituximab-mediated complement-dependent cytotoxicity.
    Guo B; Ma ZW; Li H; Xu GL; Zheng P; Zhu B; Wu YZ; Zou Q
    Clin Immunol; 2008 Aug; 128(2):155-63. PubMed ID: 18502181
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Complement and cellular cytotoxicity in antibody therapy of cancer.
    Wang SY; Weiner G
    Expert Opin Biol Ther; 2008 Jun; 8(6):759-68. PubMed ID: 18476787
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rapid degradation of the complement regulator, CD59, by a novel inhibitor.
    Cai B; Xie S; Liu F; Simone LC; Caplan S; Qin X; Naslavsky N
    J Biol Chem; 2014 Apr; 289(17):12109-12125. PubMed ID: 24616098
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumor cell expression of CD59 is associated with resistance to CD20 serotherapy in patients with B-cell malignancies.
    Treon SP; Mitsiades C; Mitsiades N; Young G; Doss D; Schlossman R; Anderson KC
    J Immunother; 2001; 24(3):263-71. PubMed ID: 11394505
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Blockade of bulky lymphoma-associated CD55 expression by RNA interference overcomes resistance to complement-dependent cytotoxicity with rituximab.
    Terui Y; Sakurai T; Mishima Y; Mishima Y; Sugimura N; Sasaoka C; Kojima K; Yokoyama M; Mizunuma N; Takahashi S; Ito Y; Hatake K
    Cancer Sci; 2006 Jan; 97(1):72-9. PubMed ID: 16367924
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CD52 over-expression affects rituximab-associated complement-mediated cytotoxicity but not antibody-dependent cellular cytotoxicity: preclinical evidence that targeting CD52 with alemtuzumab may reverse acquired resistance to rituximab in non-Hodgkin lymphoma.
    Cruz RI; Hernandez-Ilizaliturri FJ; Olejniczak S; Deeb G; Knight J; Wallace P; Thurberg BL; Kennedy W; Czuczman MS
    Leuk Lymphoma; 2007 Dec; 48(12):2424-36. PubMed ID: 18067019
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Complement-dependent cytotoxicity induced by therapeutic antibodies in B-cell acute lymphoblastic leukemia is dictated by target antigen expression levels and augmented by loss of membrane-bound complement inhibitors.
    Loeff FC; van Egmond HME; Nijmeijer BA; Falkenburg JHF; Halkes CJ; Jedema I
    Leuk Lymphoma; 2017 Sep; 58(9):1-14. PubMed ID: 28140725
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A high-affinity inhibitor of human CD59 enhances complement-mediated virolysis of HIV-1: implications for treatment of HIV-1/AIDS.
    Hu W; Yu Q; Hu N; Byrd D; Amet T; Shikuma C; Shiramizu B; Halperin JA; Qin X
    J Immunol; 2010 Jan; 184(1):359-68. PubMed ID: 19955519
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A novel hemolytic complement-sufficient NSG mouse model supports studies of complement-mediated antitumor activity in vivo.
    Verma MK; Clemens J; Burzenski L; Sampson SB; Brehm MA; Greiner DL; Shultz LD
    J Immunol Methods; 2017 Jul; 446():47-53. PubMed ID: 28390927
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CD46 and CD59 inhibitors enhance complement-dependent cytotoxicity of anti-CD38 monoclonal antibodies daratumumab and isatuximab in multiple myeloma and other B-cell malignancy cells.
    Wang H; Koob T; Fromm JR; Gopal A; Carter D; Lieber A
    Cancer Biol Ther; 2024 Dec; 25(1):2314322. PubMed ID: 38361357
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CD20 levels determine the in vitro susceptibility to rituximab and complement of B-cell chronic lymphocytic leukemia: further regulation by CD55 and CD59.
    Golay J; Lazzari M; Facchinetti V; Bernasconi S; Borleri G; Barbui T; Rambaldi A; Introna M
    Blood; 2001 Dec; 98(12):3383-9. PubMed ID: 11719378
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.